Biocon Ltd - Company Profile
Powered by 
All the data and insights you need on Biocon Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Biocon Ltd Strategy Report
- Understand Biocon Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Biocon Ltd (Biocon) is a provider of biopharmaceuticals, generic active pharmaceutical ingredients (APIs) and research services. It is an integrated healthcare company with offerings that cover the entire drug development value chain. Using its proprietary fermentation technologies, the company develops effective and innovative biomolecules in the fields of diabetes, cancer, autoimmune diseases and other therapeutic areas. Some of its key brands include Insugen, Krabeva, CanMAb, BioMAb-EGFR, Basalog One and AlzuMAb.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Biocon offers custom research and clinical research services in various fields including synthetic chemistry and molecular biology. It established Biocon Research Ltd as a wholly owned subsidiary to undertake research in biologics, antibody molecules and proteins. It has portfolio of biologics under clinical development with six biosomilars and two novels approved in developed markets of the US, EU, Japan and Australia. The company’s novel pipeline comprises Insulin Tregopil, anti-CD6 antibody and a fusion protein for immuno-oncology; Nimotuzumab, monoclonal antibody for head and neck cancer and Itolizumab, anti-CD6 monoclonal antibody. In FY2023, the company spent INR11,194 million on R&D, which grew 88% YoY, and as a percentage of revenue stood at 10%. Its key technologies encompass aseptic formulation and fill-finish, chemical synthesis, large-scale microbial fermentation, mammalian cell culture and protein and antibody purification. The company's R&D capabilities include analytical method development, bio-analytical method development in different matrices, biochemical engineering, biophysical characterization, gene cloning and expression, fermentation development, microbiology and strain improvement, non-clinical and clinical development, oral and parenteral formulation development, process development of biologicals and small molecules, recombinant microbial and mammalian cell culture, synthetic organic chemistry.
Business Segments
Overview
Manufactures and develops biosimilars and novel biologic drugs. It has a portfolio of 25 biosimilars comprising human insulin/insulin analogues, monoclonal antibodies and other biologics. Its generic insulins and biosimilars portfolio include Adalimumab, Bevacizumab, Etanercept, Filgrastim, Insulin Aspart, Insulin Glargine, Insulin Lispro, Pegfilgrastim, Recombinant Human Insulin and Trastuzumab. Also develops novel biologic drugs to address local and global unmet medical needs in the areas of diabetes, autoimmune/ inflammation and oncology. These therapeutics spans across a broad range of platforms including novel fusion MAbs; recombinant proteins, monoclonal antibodies (MAbs); and small interfering RNA (SiRNA). The biologics portfolio includes Insulin Tregopil, a Phase II ready first-in-class oral prandial insulin molecule for post-prandial glycaemic control; QPI-1007, a novel SiRNA molecule to treat non-arteritic ischemic optic neuropathy (NAION); and FmAb2, a fusion protein of EFGR mAb in pre-clinical development for multiple tumor types.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Develops and manufactures generic formulations and small molecule active pharmaceutical ingredients (APIs) comprising statins, immunosuppressants, anti-obesity, anti-diabetics, antifungals, ophthalmologicals, oncologicals, urologicals and others. Uses unique technological strengths such as fermentation science and complex chemistry to manufacture a portfolio of generic formulations.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers early and advanced stage programs in the therapeutic areas of diabetes, oncology and autoimmune/inflammatory diseases. Its portfolio includes Itolizumab, a humanized monoclonal CD6 antibody for Psorasis; Nimotuzumab, monoclonal antibody for head and neck cancer and BCA101, first-in class EGFR / TGFß-trap bifunctional antibody which is in Phase I/II clinical study.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers drug discovery and development services for the novel molecular entities (NMEs). The segment serves hundreds of clients including start-up companies, large pharmaceutical and biotechnology firms, chemical, nutrition, agrochemical and animal health companies in the US, Europe and Asia Pacific. Provides services through, Syngene International Ltd (Syngene), one of India’s leading contract research organization. Syngene supports clients in conducting discovery (from hit to candidate selection), development (including analytical and bio-analytical evaluation, pre-clinical and clinical studies, formulation development and stability studies) and pilot manufacturing (scale-up, pre-clinical and clinical supplies).
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer